Fosun has exclusive rights to not just China but Greater China, which was why Taiwan was complaining earlier about China “politically influencing” BioNtech to not directly sell them the vaccine.Fosun invested in BioNtech and received 1.58 million shares of BioNtech. In addition, Fosun would have the exclusive rights of BioNtech vaccines in China. BioNtech granted Pfizer the exclusive rights of all other regions of its mRNA vaccines.
Fosun would conduct trials for BNT162b1 version of BioNtech covid vaccine in China but BNT162b2 which trials was conducted by Pfizer has a better safety results. Consequently, Fosun abandoned BNT162b1 and switched to BNT162b2. As a result, Fosun was forced to conduct BNT162b2 trials in China all over again for the clinical trial 1&2 phases.